Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study.

Paciullo F, Bury L, Noris P, Falcinelli E, Melazzini F, Orsini S, Zaninetti C, Abdul-Kadir R, Obeng-Tuudah D, Heller P, Glembotsky AC, Fabris F, Rivera J, Lozano ML, Butta N, Favier R, Cid AR, Fouassier M, Podda GM, Santoro C, Grandone E, Henskens Y, Nurden P, Zieger B, Cuker A, Devreese K, Tosetto A, De Candia E, Dupuis A, Miyazaki K, Othman M, Gresele P.

Haematologica. 2019 Sep 26. pii: haematol.2019.227876. doi: 10.3324/haematol.2019.227876. [Epub ahead of print]

2.

Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis.

Chiasakul T, De Jesus E, Tong J, Chen Y, Crowther M, Garcia D, Chai-Adisaksopha C, Messé SR, Cuker A.

J Am Heart Assoc. 2019 Oct;8(19):e012877. doi: 10.1161/JAHA.119.012877. Epub 2019 Sep 24.

3.

The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia.

Pishko AM, Lefler DS, Gimotty P, Paydary K, Fardin S, Arepally GM, Crowther M, Rice L, Vega R, Cines DB, Guevara JP, Cuker A.

J Thromb Haemost. 2019 Jul 27. doi: 10.1111/jth.14587. [Epub ahead of print]

PMID:
31350937
4.

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial.

Escuriola Ettingshausen C, Hegemann I, Simpson ML, Cuker A, Kulkarni R, Pruthi RK, Garly ML, Meldgaard RM, Persson P, Klamroth R.

Res Pract Thromb Haemost. 2019 Mar 23;3(2):268-276. doi: 10.1002/rth2.12192. eCollection 2019 Apr.

5.

Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum.

Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz S.

Am J Hematol. 2019 Jun;94(6):697-709. doi: 10.1002/ajh.25475. Epub 2019 Apr 16. Review.

PMID:
30916798
6.

Why plasma-derived factor VIII?

Aledort L, Carpenter SL, Cuker A, Kulkarni R, Recht M, Young G, Leissinger C.

Haemophilia. 2019 May;25(3):e183-e185. doi: 10.1111/hae.13705. Epub 2019 Mar 13. No abstract available.

PMID:
30866124
7.

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.

Cuker A, Bass AD, Nadj C, Agius MA, Steingo B, Selmaj KW, Thoits T, Guerreiro A, Van Wijmeersch B, Ziemssen T, Meuth SG, LaGanke CC, Thangavelu K, Rodriguez CE, Baker DP, Margolin DH, Jannsens A.

Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612. [Epub ahead of print]

PMID:
30785358
8.

Structured decision-making drives guidelines panels' recommendations "for" but not "against" health interventions.

Djulbegovic B, Reljic T, Elqayam S, Cuker A, Hozo I, Zhou Q, Li SA, Alexander P, Nieuwlaat R, Wiercioch W, Schünemann H, Guyatt G.

J Clin Epidemiol. 2019 Jun;110:23-33. doi: 10.1016/j.jclinepi.2019.02.009. Epub 2019 Feb 16.

PMID:
30779950
9.

Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine.

Coppo P, Cuker A, George JN.

Res Pract Thromb Haemost. 2018 Nov 16;3(1):26-37. doi: 10.1002/rth2.12160. eCollection 2019 Jan. Review.

10.

Clinical and laboratory diagnosis of TTP: an integrated approach.

Chiasakul T, Cuker A.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):530-538. doi: 10.1182/asheducation-2018.1.530. Review.

PMID:
30504354
11.

American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, Warkentin TE, Wex A, Mustafa RA, Morgan RL, Santesso N.

Blood Adv. 2018 Nov 27;2(22):3360-3392. doi: 10.1182/bloodadvances.2018024489.

12.

Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia.

Pishko AM, Fardin S, Lefler DS, Paydary K, Vega R, Arepally GM, Crowther M, Rice L, Cines DB, Cuker A.

Blood Adv. 2018 Nov 27;2(22):3155-3162. doi: 10.1182/bloodadvances.2018023077.

13.

How can we reverse bleeding in patients on direct oral anticoagulants?

Crowther M, Cuker A.

Kardiol Pol. 2019;77(1):3-11. doi: 10.5603/KP.a2018.0197. Epub 2018 Oct 19. Review.

14.

Evidence to Decision framework provides a structured "roadmap" for making GRADE guidelines recommendations.

Li SA, Alexander PE, Reljic T, Cuker A, Nieuwlaat R, Wiercioch W, Guyatt G, Schünemann HJ, Djulbegovic B.

J Clin Epidemiol. 2018 Dec;104:103-112. doi: 10.1016/j.jclinepi.2018.09.007. Epub 2018 Sep 22.

PMID:
30253221
15.

Neutrophil accumulation and NET release contribute to thrombosis in HIT.

Gollomp K, Kim M, Johnston I, Hayes V, Welsh J, Arepally GM, Kahn M, Lambert MP, Cuker A, Cines DB, Rauova L, Kowalska MA, Poncz M.

JCI Insight. 2018 Sep 20;3(18). pii: 99445. doi: 10.1172/jci.insight.99445. eCollection 2018 Sep 20.

16.

The role of scientific publishing in the development of early career investigators.

Cuker A, Ay C, Cushman M.

Res Pract Thromb Haemost. 2017 Dec 27;2(1):6-7. doi: 10.1002/rth2.12072. eCollection 2018 Jan. No abstract available.

17.

T2 Magnetic Resonance to Monitor Hemostasis.

Cuker A, Marturano JE, Carinato ME, Lowery TJ, Cines DB.

Semin Thromb Hemost. 2019 Apr;45(3):247-252. doi: 10.1055/s-0038-1667114. Epub 2018 Aug 17.

PMID:
30119137
18.

The case for catheter-directed thrombolysis in selected patients with acute proximal deep vein thrombosis.

Chiasakul T, Cuker A.

Blood Adv. 2018 Jul 24;2(14):1799-1802. doi: 10.1182/bloodadvances.2018018622. Review. No abstract available.

19.

A cross-sectional analysis of cardiovascular disease in the hemophilia population.

Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang TF, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Wheeler A, Kouides P, Escobar MA, Leissinger C, Galdzicka S, Corson M, Watson C, Konkle BA.

Blood Adv. 2018 Jun 12;2(11):1325-1333. doi: 10.1182/bloodadvances.2018018226.

20.

Clot stability as a determinant of effective factor VIII replacement in hemophilia A.

Leong L, Chernysh IN, Xu Y, Sim D, Nagaswami C, de Lange Z, Kosolapova S, Cuker A, Kauser K, Weisel JW.

Res Pract Thromb Haemost. 2017 Oct;1(2):231-241. doi: 10.1002/rth2.12034. Epub 2017 Aug 10.

21.

Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system.

Grant SJ, Kothari S, Gimotty PA, Gooneratne NS, Cuker A.

J Thromb Thrombolysis. 2018 Jul;46(1):1-6. doi: 10.1007/s11239-018-1651-0.

PMID:
29611105
22.

Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologist-oncologists.

Pishko AM, Misgav M, Cuker A, Cines DB, George JN, Vesely SK, Terrell DR.

J Thromb Thrombolysis. 2018 Jul;46(1):24-30. doi: 10.1007/s11239-018-1649-7.

23.

Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices.

Cuker A.

Am J Hematol. 2018 Jun;93(6):816-823. doi: 10.1002/ajh.25092. Epub 2018 Apr 15. Review.

24.

Statins for high cholesterol … and for low platelets?

Nazy I, Cuker A.

Blood. 2018 Mar 15;131(11):1159-1161. doi: 10.1182/blood-2018-01-824888. No abstract available.

PMID:
29545404
25.

How I manage patients with anticoagulation-associated bleeding or urgent surgery.

Sauter TC, Eberle B, Wuillemin WA, Thiele T, Angelillo-Scherrer A, Exadaktylos AK, Erdoes G, Cuker A, Nagler M.

Swiss Med Wkly. 2018 Mar 14;148:w14598. doi: 10.4414/smw.2018.14598. eCollection 2018. Review.

26.

Chart validation of inpatient International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) administrative diagnosis codes for venous thromboembolism (VTE) among intravenous immune globulin (IGIV) users in the Sentinel Distributed Database.

Ammann EM, Cuker A, Carnahan RM, Perepu US, Winiecki SK, Schweizer ML, Leonard CE, Fuller CC, Garcia C, Haskins C, Chrischilles EA.

Medicine (Baltimore). 2018 Feb;97(8):e9960. doi: 10.1097/MD.0000000000009960.

27.

Prevalence of and risk factors for cerebral microbleeds among adult patients with haemophilia A or B.

Husseinzadeh H, Chiasakul T, Gimotty PA, Pukenas B, Wolf R, Kelty M, Chiang E, Fogarty PF, Cuker A.

Haemophilia. 2018 Mar;24(2):271-277. doi: 10.1111/hae.13398. Epub 2017 Dec 28.

PMID:
29282815
28.

Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.

George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA.

N Engl J Med. 2017 Dec 7;377(23):2215-2227. doi: 10.1056/NEJMoa1708538.

29.

2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS.

J Am Coll Cardiol. 2017 Dec 19;70(24):3042-3067. doi: 10.1016/j.jacc.2017.09.1085. Epub 2017 Dec 1. Review. No abstract available.

30.

Comparative Effectiveness of Enoxaparin vs Dalteparin for Thromboprophylaxis After Traumatic Injury.

Miano TA, Cuker A, Christie JD, Martin N, Smith B, Makley AT, Guo W, Hennessy S.

Chest. 2018 Jan;153(1):133-142. doi: 10.1016/j.chest.2017.08.008. Epub 2017 Aug 18.

31.

Clinical Scoring Systems in Thrombosis and Hemostasis.

Cuker A.

Semin Thromb Hemost. 2017 Jul;43(5):447-448. doi: 10.1055/s-0037-1602661. Epub 2017 Jun 23. No abstract available.

PMID:
28645129
32.

Prevalence and impact of obesity in people with haemophilia: Review of literature and expert discussion around implementing weight management guidelines.

Kahan S, Cuker A, Kushner RF, Maahs J, Recht M, Wadden T, Willis T, Majumdar S, Ungar D, Cooper D.

Haemophilia. 2017 Nov;23(6):812-820. doi: 10.1111/hae.13291. Epub 2017 Jun 21. Review.

PMID:
28636076
33.

Heparin-Induced Thrombocytopenia in Cardiac Surgery Patients.

Pishko AM, Cuker A.

Semin Thromb Hemost. 2017 Oct;43(7):691-698. doi: 10.1055/s-0037-1602664. Epub 2017 Jun 8. Review. No abstract available.

34.

Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.

Li R, Panckeri KA, Fogarty PF, Cuker A, Diamond SL.

Haemophilia. 2017 Sep;23(5):759-768. doi: 10.1111/hae.13259. Epub 2017 May 5.

35.

Laboratory measurement of the direct oral anticoagulants: Indications and impact on management in clinical practice.

Wright C, Brown R, Cuker A.

Int J Lab Hematol. 2017 May;39 Suppl 1:31-36. doi: 10.1111/ijlh.12654.

PMID:
28447413
36.

Diagnostic accuracy of IgG-specific versus polyspecific enzyme-linked immunoassays in heparin-induced thrombocytopenia: a systematic review and meta-analysis.

Husseinzadeh HD, Gimotty PA, Pishko AM, Buckley M, Warkentin TE, Cuker A.

J Thromb Haemost. 2017 Jun;15(6):1203-1212. doi: 10.1111/jth.13692. Epub 2017 May 11. Review.

37.

Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism.

Crowther MA, Cuker A.

N Engl J Med. 2017 Mar 30;376(13):1279-1280. doi: 10.1056/NEJMe1701628. Epub 2017 Mar 18. No abstract available.

PMID:
28316277
38.

Profile of Instrumentation Laboratory's HemosIL® AcuStar HIT-Ab(PF4-H) assay for diagnosis of heparin-induced thrombocytopenia.

Nagler M, Cuker A.

Expert Rev Mol Diagn. 2017 May;17(5):419-426. doi: 10.1080/14737159.2017.1304213. Epub 2017 Mar 16. Review.

PMID:
28271738
39.

Rapid Evaluation of Platelet Function With T2 Magnetic Resonance.

Cuker A, Husseinzadeh H, Lebedeva T, Marturano JE, Massefski W, Lowery TJ, Lambert MP, Abrams CS, Weisel JW, Cines DB.

Am J Clin Pathol. 2016 Dec;146(6):681-693. doi: 10.1093/ajcp/aqw189. Epub 2016 Dec 27.

40.

Inappropriate documentation of heparin allergy in the medical record because of misdiagnosis of heparin-induced thrombocytopenia: frequency and consequences.

McMahon CM, Tanhehco YC, Cuker A.

J Thromb Haemost. 2017 Feb;15(2):370-374. doi: 10.1111/jth.13565. Epub 2016 Dec 24.

41.

Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study.

James PD, Mahlangu J, Bidlingmaier C, Mingot-Castellano ME, Chitlur M, Fogarty PF, Cuker A, Mancuso ME, Holme PA, Grabell J, Satkunam N, Hopman WM, Mathew P; Global Emerging HEmostasis Experts Panel (GEHEP).

Haemophilia. 2016 Nov;22(6):912-918. doi: 10.1111/hae.13089.

PMID:
27868369
42.

Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia.

Cines DB, Yarovoi SV, Zaitsev SV, Lebedeva T, Rauova L, Poncz M, Arepally GM, Khandelwal S, Stepanova V, Rux AH, Cuker A, Guo C, Ocariza LM, Travers RJ, Smith SA, Kim H, Morrissey JH, Conway EM.

Blood Adv. 2016 Nov 22;1(1):62-74. doi: 10.1182/bloodadvances.2016000877. eCollection 2016 Nov 29.

43.

Management of the multiple phases of heparin-induced thrombocytopenia.

Cuker A.

Thromb Haemost. 2016 Oct 28;116(5):835-842. Epub 2016 Apr 14. Review.

PMID:
27075525
44.

Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.

Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA.

Chest. 2017 Jan;151(1):127-138. doi: 10.1016/j.chest.2016.08.1462. Epub 2016 Sep 13. Review.

45.

Measurement and reversal of the direct oral anticoagulants.

Samuelson BT, Cuker A.

Blood Rev. 2017 Jan;31(1):77-84. doi: 10.1016/j.blre.2016.08.006. Epub 2016 Sep 2. Review.

46.

Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients.

Tarantino MD, Cuker A, Hardesty B, Roberts JC, Sholzberg M.

Haemophilia. 2017 Jan;23(1):25-32. doi: 10.1111/hae.13040. Epub 2016 Aug 10.

PMID:
27511890
47.

Management of Periprocedural Anticoagulation: A Survey of Contemporary Practice.

Flaker GC, Theriot P, Binder LG, Dobesh PP, Cuker A, Doherty JU.

J Am Coll Cardiol. 2016 Jul 12;68(2):217-26. doi: 10.1016/j.jacc.2016.04.042. Review.

48.

Controversies in the treatment of immune thrombocytopenia.

Cuker A, Cines DB, Neunert CE.

Curr Opin Hematol. 2016 Sep;23(5):479-85. doi: 10.1097/MOH.0000000000000270. Review.

PMID:
27380558
49.

Adjuvant rituximab to prevent TTP relapse.

Cuker A.

Blood. 2016 Jun 16;127(24):2952-3. doi: 10.1182/blood-2016-04-710475. No abstract available.

PMID:
27313327
50.

How I treat refractory immune thrombocytopenia.

Cuker A, Neunert CE.

Blood. 2016 Sep 22;128(12):1547-54. doi: 10.1182/blood-2016-03-603365. Epub 2016 Apr 6.

PMID:
27053529

Supplemental Content

Support Center